Blog Posts focused on: Sound Life Project (SLP); Type 1 Diabetes (T1D); Biorepository
New Grant Fuels Research Into Preventing Autoimmunity
Naive T cells are like the rookies of your immune system. They’re young and inexperienced. They grow up to do different jobs, most of which help protect your body from viruses and bacteria. But a few stray down the wrong path — growing up to become cells that cause autoimmune disease.
On the Brink of a Golden Age of Medicine
"I know we will reach that golden age, and BRI’s research in human immunology is the vehi¬cle that will take us there. This field has shepherded incredible advances in recent years, including new vaccines, new cancer treatments, and new and better treatment options for autoimmune disease."
Participants Like Mikaela Fuel Research Advances
Participating in a clinical trial for type 1 diabetes (T1D) was easy for 9-year-old Mikaela. “Everyone was really nice. I just had to drink a milkshake with some medicine in it and get an IV.
An Insider's Look Into Clinical Trials at BRI
Before medicines become widely available, they have to be rigorously tested — first in the lab, then in people through clinical trials.
To Belgium and Back Again to Study Beta Cells
BRI researchers are working to develop a groundbreaking new approach to treat type 1 diabetes (T1D). They aim to turn T cells that cause T1D into regulatory T cells (Tregs) that protect you from T1D.
Using Epidemiology to Fight Pancreas Cancer
It only took one statistic to get Meg Mandelson, PhD, interested in studying pancreas cancer. “Five-year survival rates have greatly improved for almost every cancer over the past two decades,” she says. “Pancreas cancer is one of the few that hasn’t.”
Prediction and Prevention: A New Paradigm in Autoimmune Disease
The FDA recently approved teplizumab, a groundbreaking therapy that signals a paradigm shift in treating not only T1D but all autoimmune diseases.
A Promising New Approach to Stopping Type 1 Diabetes
A new study, led by a BRI researcher and published in Science Translational Medicine, put engineered t-regulatory cells to the test. In lab tests, the research team found that the engineered cells controlled the cells that attack the pancreas in T1D patients.
Teplizumab FAQ: Your Questions Answered About New Therapy to Delay T1D
Scientists at the Benaroya Research Institute (BRI) and TrialNet, a global type 1 diabetes (T1D) research consortium, have spent decades working to answer a bold question: Can we stop T1D before it starts?
Honoring Family with an Endowment for T1D Research
When Nina and Georg Pedersen were writing charitable gifts into their will, they had two goals: finding meaningful ways to honor their family and recognizing the expert care they’ve received at Virginia Mason.